Pharmaceutical Composition

A pharmaceutical composition with specific bacterial cells and disintegrants addresses the disintegration issues in solid preparations, improving their dissolution properties and consistency.

JP7583498B1Active Publication Date: 2024-11-14MIYARISAN PHARMACEUTICAL CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024524394
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-11-16
Publication Date
2024-11-14
Estimated Expiration
2043-11-16

AI Technical Summary

Technical Problem

Solid pharmaceutical preparations containing microorganisms face issues with decreased disintegration properties when the microorganism content is increased.

Method used

A pharmaceutical composition is formulated with bacterial cells and a specific range of disintegrants, such as croscarmellose sodium, crospovidone, and sodium starch glycolate, within certain content percentages to improve disintegration properties.

Benefits of technology

The composition enhances the disintegration properties of solid preparations, ensuring consistent and efficient dissolution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583498000006
    Figure 0007583498000006
  • Figure 0007583498000007
    Figure 0007583498000007
  • Figure 0007583498000008
    Figure 0007583498000008
Patent Text Reader

Abstract

The present invention provides a new formulation composition capable of improving the disintegration property of a solid formulation, comprising a bacterial cell, at least one disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate, and an excipient (excluding croscarmellose sodium, crospovidone, and sodium starch glycolate), wherein the content of the bacterial cell is 3.0% by mass or more and 35.0% by mass or less, and when the content of the bacterial cell is 3.0% by mass or more and 29.5% by mass or less, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, and when the content of the bacterial cell is more than 29.5% by mass and 35.0% by mass or less, the content of the disintegrant is 10.0% by mass or more and 14.0% by mass or less.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to pharmaceutical compositions. [Background technology]

[0002] One type of formulation is a solid formulation. A solid formulation is a commonly used dosage form, and refers to a solid-state formulation such as a capsule or tablet. A solid formulation contains medicinal ingredients, active ingredients, and additives such as excipients.

[0003] Microorganisms have been attracting attention as one of the medicinal and active ingredients of pharmaceutical preparations. Probiotics, which are "live microorganisms that have a positive effect on the health of the host by improving the balance of the intestinal flora," are being used as such microorganisms.

[0004] In solid preparations containing microorganisms, the content of the microorganism in the solid preparation is changed depending on the situation. However, when the content of the microorganism is increased, the disintegration property of the solid preparation may be decreased.

[0005] In order to solve such problems, JP 2022-031035 A discloses a tablet containing lactic acid bacteria powder, maltose powder, and a binder in a specific ratio. Summary of the Invention

[0006] An object of the present invention is to provide a novel formulation composition capable of improving the disintegration property of a solid formulation.

[0007] The present inventors have surprisingly found that the disintegration property of a solid preparation can be improved by setting the content of a specific disintegrant relative to the content of bacteria (microorganisms) within a specific range. Based on this finding, the present invention has been completed.

[0008] That is, according to one embodiment of the present invention, there is provided a formulation composition comprising bacterial cells, at least one disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate, and an excipient (excluding croscarmellose sodium, crospovidone, and sodium starch glycolate), wherein the content of the bacterial cells is 3.0% by mass or more and 35.0% by mass or less, and when the content of the bacterial cells is 3.0% by mass or more and 29.5% by mass or less, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, and when the content of the bacterial cells is more than 29.5% by mass and 35.0% by mass or less, the content of the disintegrant is 10.0% by mass or more and 14.0% by mass or less. [Brief description of the drawings]

[0009] [Figure 1] 1 is a graph showing the results of a disintegration test of the capsule of Comparative Example 1. [Diagram 2] 1 is a graph showing the results of a disintegration test of the capsule of Comparative Example 2. [Diagram 3] 1 is a graph showing the results of capsule disintegration tests for Examples 4 to 5 and Comparative Examples 3 to 8. [Figure 4] 1 is a graph showing the results of a disintegration test of the capsules of Examples 6 to 8. [Diagram 5] 1 is a graph showing the results of a disintegration test of the capsules of Examples 9 and 10. [Figure 6] 1 is a graph showing the measurement results of the filling amounts of capsules in Examples 3 and 11. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] An embodiment according to one aspect of the present invention will be described below, but the present invention is not limited to the following embodiment.

[0011] In this specification, the range "X to Y" means "X or more and Y or less." Furthermore, unless otherwise specified, the operations and measurements of physical properties are performed under conditions of room temperature (20 to 25°C) and relative humidity of 40 to 50% RH.

[0012] <Formulation composition> One embodiment of the present invention relates to a formulation composition comprising a bacterial cell, at least one disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate, and an excipient (excluding croscarmellose sodium, crospovidone, and sodium starch glycolate), wherein the content of the bacterial cell is 3.0% by mass or more and 35.0% by mass or less, and when the content of the bacterial cell is 3.0% by mass or more and 29.5% by mass or less, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, and when the content of the bacterial cell is more than 29.5% by mass and 35.0% by mass or less, the content of the disintegrant is 10.0% by mass or more and 14.0% by mass or less. This configuration can improve the disintegration property of a solid formulation.

[0013] In this specification, "at least one disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate" is also simply referred to as "the disintegrant of the present invention."

[0014] In this specification, when disintegrants other than "croscarmellose sodium, crospovidone, and sodium starch glycolate" have uses as excipients, these disintegrants are treated as excipients.

[0015] In this specification, when the formulation composition according to the present invention contains the bacterial cells in the form of a bacterial powder, the components in the powder other than the bacterial cells are treated as the corresponding components (disintegrants, excipients, lubricants or other components).

[0016] The formulation composition of the present invention comprises bacterial cells.

[0017] The bacterial cells are not particularly limited, and any bacterial cells used in pharmaceutical preparations can be used. The bacterial cells are preferably at least one type of bacterial cell selected from the group consisting of butyric acid bacteria, lactic acid bacteria, and bifidobacteria.

[0018] An example of the butyric acid bacteria is a non-pathogenic butyric acid bacteria belonging to the genus Clostridium. A specific example of the butyric acid bacteria is Clostridium butyricum. Butyric acid bacteria are known and can be obtained by a conventional method.

[0019] Specific examples of Clostridium butyricum include Clostridium butyricum MIYAIRI 588 (FERM BP-2789), Clostridium butyricum NIP1020, Clostridium butyricum NIP1021, Clostridium butyricum (FERM P-11868), Clostridium butyricum (FERM P-11868), Clostridium butyricum (FERM P-11869), Clostridium butyricum (FERM P-11870), Clostridium butyricum ATCC859 (Clostridium butyricum ATCC859, Clostridium butyricum NBRC3315, Clostridium butyricum ATCC860, Clostridium butyricum ATCC19398, etc. All of these are deposited and stored at the Patent Microorganisms Depositary Center of the National Institute of Technology and Evaluation. The Clostridium butyricum is preferably one or more selected from the group consisting of Clostridium butyricum MIYAIRI 588 (FERM BP-2789), Clostridium butyricum MIYAIRI 585 (FERM BP-06815), Clostridium butyricum MIYAIRI 595 (FERM BP-06816) and Clostridium butyricum MIYAIRI 630 (FERM BP-06817), and more preferably Clostridium butyricum MIYAIRI 588 (FERM BP-2789).Clostridium butyricum Miyairi 588 strain was deposited on May 1, 1981 at the Microbial Industrial Technology Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently the Patent Organism Depositary Center, National Institute of Technology and Evaluation, Room 120, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818, Japan) under the accession number FERM BP-2789, and transferred to an international depositary institution under the Budapest Treaty on March 6, 1990, where it is deposited under the accession number FERM BP-2789.

[0020] Examples of lactic acid bacteria include non-pathogenic lactic acid bacteria belonging to the genera Lactobacillus and Enterococcus. Specific examples of lactic acid bacteria include Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus rhamnosus, Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus curvatus, Lactobacillus reuteri, and Lactobacillus brevis. Examples of lactic acid bacteria include Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus delbrueckii, Lactobacillus helveticus, Lactobacillus salibarius, Lactobacillus farciminis, Enterococcus faecalis, and Enterococcus faecium. These lactic acid bacteria are known and can be obtained by conventional methods.

[0021] Examples of bifidobacteria include non-pathogenic bifidobacteria belonging to the genus Bifidobacterium. Specific examples of bifidobacteria include Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium lactis, and Bifidobacterium animalis. These bifidobacteria are known and can be obtained by conventional methods.

[0022] In the formulation composition according to the present invention, the content of the bacterial cells is 3.0% by mass or more and 35.0% by mass or less, based on the total mass of the formulation composition. The content of the bacterial cells may be 4.0% by mass or more and 34.0% by mass or less, 8.0% by mass or more and 34.0% by mass or less, 20.0% by mass or more and 34.0% by mass or less, or 25.0% by mass or more and 34.0% by mass or less, based on the total mass of the formulation composition.

[0023] In the formulation composition of the present invention, the bacterial cells are preferably in the form of a dry product (bacterial powder), more preferably in the form of a dry product prepared by spray drying or fluidized bed granulation. The method for making the bacterial cells into a dry product (preferably spray drying and fluidized bed granulation) is not particularly limited, and any conventionally known method can be used. In this specification, the excipient in the dry product of the bacterial cells is treated as the excipient described below. When the dry product of the bacterial cells further contains a disintegrant, a lubricant, and other components, the disintegrant, the lubricant, and other components are treated as the disintegrant, the lubricant, and other components described below, respectively.

[0024] The pharmaceutical composition of the present invention comprises at least one disintegrant selected from the group consisting of croscarmellose sodium, crospovidone and sodium starch glycolate.

[0025] In the formulation composition of the present invention, when the content of the bacterial cells is 3.0 mass% or more and 29.5 mass% or less, relative to the total mass of the formulation composition, the content of the disintegrant is 5.0 mass% or more and 14.0 mass% or less, relative to the total mass of the formulation composition, and when the content of the bacterial cells is more than 29.5 mass% and 35.0 mass% or less, relative to the total mass of the formulation composition, the content of the disintegrant is 10.0 mass% or more and 14.0 mass% or less, relative to the total mass of the formulation composition.

[0026] In one embodiment, When the content of the bacterial cells is 4.0% by mass or more and 29.5% by mass or less, based on the total mass of the formulation composition, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, 5.0% by mass or more and 10.0% by mass or less, or 10.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition; When the content of the bacterial cells is 8.0% by mass or more and 29.5% by mass or less, based on the total mass of the formulation composition, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, 5.0% by mass or more and 10.0% by mass or less, or 10.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition; When the content of the bacterial cells is 20.0% by mass or more and 29.5% by mass or less, based on the total mass of the formulation composition, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, 5.0% by mass or more and 10.0% by mass or less, or 10.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition; When the content of the bacterial cells is 25.0% by mass or more and 29.5% by mass or less, based on the total mass of the formulation composition, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, 5.0% by mass or more and 10.0% by mass or less, or 10.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition; When the content of the bacterial cells is more than 29.5% by mass and 34.0% by mass or less, based on the total mass of the formulation composition, the content of the disintegrant is 10.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition.

[0027] The pharmaceutical compositions of the present invention include excipients (except for croscarmellose sodium, crospovidone, and sodium starch glycolate).

[0028] In the formulation composition according to the present invention, the content of the excipient can be appropriately adjusted according to the content of the bacterial cells and the disintegrant. The content of the excipient is preferably 50.0% by mass or more and 85.0% by mass or less based on the total mass of the formulation composition.

[0029] The excipient is not particularly limited as long as it is an excipient used in pharmaceuticals. Examples of excipients include sugars and sugar alcohols such as lactose (lactose hydrate), white sugar, sucrose, glucose, candy powder, cellulose, and mannitol; starches such as wheat starch, potato starch, and corn starch; dextrins such as cyclodextrin; cellulose derivatives such as carboxymethylcellulose (CMC), hydroxyethylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, and hydroxypropylmethylcellulose; synthetic polymer compounds such as polyvinyl alcohol and polyvinylpyrrolidone; minerals (components) such as talc and light anhydrous silicic acid; and inorganic salts such as precipitated calcium carbonate.

[0030] In a preferred embodiment, the pharmaceutical composition of the present invention contains at least one of lactose hydrate and mannitol, and corn starch as excipients.

[0031] When the excipient contains at least one of lactose hydrate and mannitol, and corn starch, the content of at least one of lactose hydrate and mannitol is preferably 12.0% by mass or more and 47.0% by mass or less based on the total mass of the excipient. The content of corn starch is preferably 47.0% by mass or more and 78.0% by mass or less based on the total mass of the excipient. The mass ratio of the corn starch to at least one of the lactose hydrate and mannitol is preferably 1.0 to 6.4.

[0032] In a preferred embodiment, the pharmaceutical composition according to the present invention further comprises, as an excipient, microcrystalline cellulose in addition to at least one of lactose hydrate and mannitol and corn starch.

[0033] When the excipient further contains crystalline cellulose in addition to at least one of lactose hydrate and mannitol and corn starch, the content of crystalline cellulose is preferably 5.9% by mass or more and 9.8% by mass or less based on the total mass of the excipient. The mass ratio of crystalline cellulose to at least one of lactose hydrate and mannitol is preferably 0.12 to 0.80.

[0034] When the excipient contains at least one of lactose hydrate and mannitol, corn starch and crystalline cellulose, the content of at least one of lactose hydrate and mannitol, corn starch and crystalline cellulose relative to the total mass of the excipient is preferably 95% by mass or more and 100% by mass or less, more preferably 98% by mass or more and 100% by mass or less, and even more preferably 100% by mass.

[0035] The pharmaceutical composition of the present invention may further comprise a lubricant.

[0036] Lubricants include stearates (eg, magnesium stearate), purified talc, borax, polyethylene glycol, and the like.

[0037] In the pharmaceutical composition according to the present invention, the content of the lubricant is, for example, from 0.1% by mass to 2% by mass, and preferably from 0.5% by mass to 1.5% by mass, based on the total mass of the pharmaceutical composition.

[0038] The pharmaceutical composition according to the present invention may contain other ingredients in addition to the above-mentioned ingredients, such as additives, pharma- ceutically acceptable carriers, auxiliary ingredients, etc.

[0039] The additives include stabilizers, preservatives, wetting agents, emulsifiers, sweeteners, colorants, flavors, buffers, antioxidants, pH adjusters, binders, thickeners, dispersants, suspending agents, bacteriostatic agents, surfactants, disintegrants (excluding croscarmellose sodium, crospovidone, and sodium starch glycolate), and the like.

[0040] Examples of pharma- ceutically acceptable carriers include binders such as dextrin and cellulose; and solvents such as water and organic solvents.

[0041] Examples of auxiliary ingredients include antibiotics, vitamins (e.g., vitamin C, vitamin E), amino acids, peptides, minerals (e.g., zinc, iron, copper, manganese, etc.), nucleic acids, polysaccharides, fatty acids, herbal medicines, etc.

[0042] The method for producing the pharmaceutical composition according to the present invention is not particularly limited, and examples thereof include a method of mixing the bacterial cells, the disintegrant according to the present invention, an excipient, and, if necessary, a lubricant and other components.

[0043] The formulation composition according to the present invention is preferably used in the form of a solid formulation (oral solid formulation) because of its excellent disintegration properties. Examples of solid formulations include capsules, tablets, powders, fine granules, granules, pills, and sustained release agents. The formulation composition according to the present invention is preferably in the form of a capsule because it has good disintegration properties and can suppress the variation in the filling amount. Therefore, one embodiment of the present invention relates to a capsule containing the formulation composition according to the present invention.

[0044] The method for producing the solid preparation is not particularly limited, and a conventionally known method can be used. For example, a capsule can be produced by filling the preparation composition according to the present invention into a capsule using a capsule filling machine. A known capsule can be used as the capsule. Examples of the capsule include hydroxypropylmethylcellulose (HPMC) capsules and gelatin capsules. The size of the capsule is not particularly limited, and can be appropriately selected depending on the amount of the preparation composition to be filled. The capsule filling machine is not particularly limited, and a fully automatic capsule filling machine, a tabletop capsule filling machine, etc. can be used. It is preferable to use a fully automatic capsule filling machine for the preparation composition according to the present invention, since it can suppress the variation in the filling amount.

[0045] <Embodiment> The following are exemplary embodiments of the present invention. [1] A fungus body, at least one disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; and an excipient (excluding croscarmellose sodium, crospovidone, and sodium starch glycolate), The content of the bacterial cells is 3.0% by mass or more and 35.0% by mass or less based on the total mass of the formulation composition, When the content of the bacterial cells is 3.0% by mass or more and 29.5% by mass or less, based on the total mass of the formulation composition, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition; A formulation composition, wherein when the content of the bacterial cells is more than 29.5% by mass and 35.0% by mass or less, based on the total mass of the formulation composition, the content of the disintegrant is 10.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition. [2] The formulation composition described in [1], wherein the bacterial cells are cells of at least one type of bacteria selected from the group consisting of butyric acid bacteria, lactic acid bacteria, and bifidobacteria. [3] The formulation composition according to [1] or [2], wherein the bacterial cells are in the form of a dried product prepared by spray drying or fluidized bed granulation. [4] The formulation composition according to any one of [1] to [3], wherein the content of the excipient is 50.0% by mass or more and 85.0% by mass or less, based on the total mass of the formulation composition. [5] The formulation composition according to any one of [1] to [4], wherein the excipient comprises at least one of lactose hydrate and mannitol, and corn starch. [6] The formulation composition described in [5], wherein the content of at least one of the lactose hydrate and mannitol is 12.0% by mass or more and 47.0% by mass or less, based on the total mass of the excipient. [7] The formulation composition according to [5] or [6], wherein the mass ratio of the corn starch to at least one of the lactose hydrate and mannitol is 1.0 or more and 6.4 or less. [8] The formulation composition according to any one of claims [5] to [7], wherein the excipient further comprises crystalline cellulose. [9] The formulation composition described in [8], wherein the mass ratio of crystalline cellulose to at least one of lactose hydrate and mannitol is 0.12 or more and 0.80 or less.

[10] The formulation composition according to any one of [1] to [9], further comprising a lubricant.

[11] A capsule comprising the formulation composition according to any one of [1] to

[10] . EXAMPLES

[0046] The present invention will be described below using specific examples, but the present invention is not limited to these examples. Unless otherwise specified, the operations were carried out at room temperature (25° C.).

[0047] <Material> (fungal powder) Clostridium butyricum MIYAIRI 588 (FERM BP-2789) powder (Preparation method: spray drying, bacterial content: 42.1% by mass, excipient content: 57.9% by mass) (Excipients) ·Lactose hydrate (Sheffield TM Spray Dried 315, KERRY GROUP PLC, Tralee) Cornstarch (Cornstarch White W-4P, Japan Cornstarch Co., Ltd.) Crystalline cellulose (Ceolas PH-101, Asahi Kasei Corporation) (Disintegrant) Croscarmellose sodium (Kiccolate ND-2HS, Asahi Kasei Corporation) Crospovidone (Kollidon CL, BASF Japan Ltd.) Sodium starch glycolate (Primojel, DFE Pharma GmbH&Co.KG, Goch) (lubricant) Magnesium stearate (Magnesium stearate-S, NOF Corporation) (capsule) · Hypromellose Capsule No. 3 (Medical HPMC Capsule QUALI-V, Qualicaps Co., Ltd.).

[0048] <Preparation of Capsules> Each material was added to a bag in the mass percentage shown in Table 1, and mixed by inversion for 2 minutes to prepare a formulation composition. The formulation composition and hypromellose capsules were added to a capsule filling machine (F-40, Qualicaps Co., Ltd.) to prepare capsules (approximately 246 mg (contents 200 mg), length approximately 15.8 mm). The operating speed was set to 40,000 cap / h.

[0049] [Table 1-1]

[0050] [Table 1-2]

[0051] [Table 1-3]

[0052] <Disintegration test> The disintegration test was carried out using a disintegration tester (NT-610, Toyama Sangyo Co., Ltd., Osaka Prefecture) according to the capsule disintegration test method 6.09 Disintegration Test Method in the 18th Revised Japanese Pharmacopoeia. Purified water was used in the test, and the test conditions were a temperature of 37±2°C and no auxiliary plate. The disintegration time was defined as the time required for the capsule or its contents to completely disappear from the stainless steel mesh of the tester. The test was carried out once for each sample, and the average disintegration time of six capsules was calculated.

[0053] FIG. 1 shows the test results of the capsules of Comparative Example 1 (operating time: 15 minutes), and FIG. 2 shows the test results of the capsules of Comparative Example 2 (operating time: 0 minutes). Table 2 also shows the test results of the capsules of Examples 1 to 3 (operating time: 0 minutes, 5 minutes, or 15 minutes). The operating time indicates the time period during which the capsules were produced. An operating time of 0 minutes indicates that the capsules were produced between 0 seconds and 59 seconds after the start of production, an operating time of 5 minutes indicates that the capsules were produced between 4 minutes and 0 seconds and 4 minutes and 59 seconds after the start of production, and an operating time of 15 minutes indicates that the capsules were produced between 15 minutes and 0 seconds and 15 minutes and 59 seconds after the start of production.

[0054] As shown in Figures 1 and 2, it is clear that the capsules of Comparative Examples 1 and 2 exceed the standard value (20 minutes) set forth in the Japanese Pharmacopoeia.

[0055] On the other hand, as shown in Table 2, it is understood that the capsules of Examples 1 to 3 contain 10% by mass of a disintegrant (croscarmellose sodium), and thus the disintegrability is improved.

[0056] [Table 2]

[0057] FIG. 3 shows the test results for the capsules of Examples 4 to 5 and Comparative Examples 3 to 8 (operation time: 5 minutes).

[0058] As shown in FIG. 3, in the capsules of Comparative Examples 3 to 6 (microbial cell content: 0.8% by mass or 2.1% by mass), the disintegration time was extended by adding 10% by mass of a disintegrant (croscarmellose sodium).

[0059] Furthermore, in the capsules of Examples 4 to 5 and Comparative Examples 7 to 8 (bacterial cell content: 4.2% by mass or 8.4% by mass), it can be seen that the disintegration properties were improved by including 10% by mass of a disintegrant (croscarmellose sodium) in Examples 4 to 5.

[0060] 4 shows the test results of the capsules of Examples 6 to 8 (operation time: 0 or 5 minutes). The capsule of Example 6 contains crospovidone as a disintegrant, the capsule of Example 7 contains sodium starch glycolate as a disintegrant, and the capsule of Example 8 contains croscarmellose sodium as a disintegrant.

[0061] As shown in FIG. 4, it can be seen that crospovidone and sodium starch glycolate can improve the disintegration property in the same way as croscarmellose sodium.

[0062] FIG. 5 shows the test results for the capsules of Examples 9 and 10 (operation time: 0 or 5 minutes).

[0063] As shown in FIG. 5, when the bacterial cell content was 25.3% by mass (Example 9) or 29.5% by mass (Example 10), the disintegration property was improved by including 5% by mass of a disintegrant (croscarmellose sodium).

[0064] Table 3 shows the test results for the capsules of Examples 3 and 11 and Comparative Example 9 (operating time: 0 minutes, 5 minutes, 10 minutes or 15 minutes (Example 3 and Comparative Example 9), operating time: 0 minutes, 5 minutes or 10 minutes (Example 11)).

[0065] As shown in Table 3, when the bacterial content was 33.7% by mass, the addition of 5% by mass of disintegrant (croscarmellose sodium) did not sufficiently improve disintegrability (Comparative Example 9). On the other hand, the addition of 10% by mass (Example 3) and 14% by mass (Example 11) of disintegrant (croscarmellose sodium) improved disintegrability.

[0066] [Table 3]

[0067] <Measurement of filling amount> For 10 capsules (Examples 3 and 11), the mass of the contents of each capsule (operation time: 0 min, 5 min, 10 min, or 15 min) was measured using an electronic balance (GH-252, A&D Co., Ltd., Tokyo), and the average value and standard deviation were calculated. The results are shown in Figure 6.

[0068] As shown in FIG. 6, it is clear that the capsules using the formulation compositions of Examples 3 and 11 can suppress variation in the filling amount.

Claims

1. The fungus body, at least one disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; and an excipient (excluding croscarmellose sodium, crospovidone, and sodium starch glycolate), The content of the bacterial cells is 3.0% by mass or more and 35.0% by mass or less based on the total mass of the formulation composition, When the content of the bacterial cells is 3.0% by mass or more and 29.5% by mass or less, based on the total mass of the formulation composition, the content of the disintegrant is 5.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition; A formulation composition for capsules, wherein when the content of the bacterial cells is more than 29.5% by mass and not more than 35.0% by mass, based on the total mass of the formulation composition, the content of the disintegrant is 10.0% by mass or more and 14.0% by mass or less, based on the total mass of the formulation composition.

2. 2. The capsule formulation composition according to claim 1, wherein the bacterial cells are cells of at least one type of bacteria selected from the group consisting of butyric acid bacteria, lactic acid bacteria, and bifidobacteria.

3. 2. The capsule formulation composition according to claim 1, wherein the bacterial cells are in the form of a dry product prepared by spray drying or fluidized bed granulation.

4. 2. The pharmaceutical composition for capsules according to claim 1, wherein the content of the excipient is 50.0% by mass or more and 85.0% by mass or less based on the total mass of the pharmaceutical composition.

5. The capsule formulation composition according to claim 1 , wherein the excipient comprises at least one of lactose hydrate and mannitol, and corn starch.

6. The content of at least one of the lactose hydrate and the mannitol is based on the total mass of the excipient. The pharmaceutical composition for capsules according to claim 5, wherein the content is 12.0% by mass or more and 47.0% by mass or less, based on the total mass of the composition.

7. 6. The composition according to claim 5, wherein a mass ratio of the corn starch to at least one of the lactose hydrate and the mannitol is 1.0 or more and 6.4 or less.

8. The capsule formulation composition according to claim 5 , wherein the excipient further comprises crystalline cellulose.

9. 9. The pharmaceutical composition for capsules according to claim 8, wherein a mass ratio of the crystalline cellulose to at least one of the lactose hydrate and mannitol is 0.12 or more and 0.80 or less.

10. The capsule formulation composition according to claim 1, further comprising a lubricant.

11. A capsule comprising the capsule formulation composition according to any one of claims 1 to 10 (excluding capsules containing low-substituted hydroxypropylcellulose).

Citation Information

Patent Citations

  • Oral dosage forms

    JP2018021000A

  • Bacteroides fragilis for Relieving Endotoxin Infection and Application Thereof

    US20210038655A1

  • Bacteria-containing oral rapidly disintegrating tablet

    WO2017006935A1

  • Solid dosage forms with improved disintegration profiles

    WO2021146523A1